These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33069075)

  • 1. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
    Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
    Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
    Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
    Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
    Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.
    Li Z; Guo M; Cao M; Zhao T; Li M; Zhai X
    Bioorg Med Chem; 2021 May; 37():116108. PubMed ID: 33756437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties.
    Lei H; Jiang N; Miao X; Xing L; Guo M; Liu Y; Xu H; Gong P; Zuo D; Zhai X
    Eur J Med Chem; 2019 Jun; 171():297-309. PubMed ID: 30927566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.
    Li T; Li C; Yang J; Guo M; Cao Z; Wang X; Jiang N; Zhai X
    Bioorg Med Chem; 2021 Oct; 47():116396. PubMed ID: 34534734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects.
    Lei H; Jia F; Cao M; Wang J; Guo M; Zhu M; Zuo D; Zhai X
    Bioorg Med Chem; 2019 Oct; 27(20):115051. PubMed ID: 31492532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
    Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
    Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
    Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation N
    Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
    Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors.
    Wang X; Hu Y; Zou X; Wang P; Yue H; Guo M; Li Z; Gong P
    Bioorg Med Chem; 2022 Jul; 66():116794. PubMed ID: 35576654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.
    Geng K; Xia Z; Ji Y; Zhang RR; Sun D; Ai J; Song Z; Geng M; Zhang A
    Eur J Med Chem; 2018 Jan; 144():386-397. PubMed ID: 29288940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
    Chuang YC; Huang BY; Chang HW; Yang CN
    Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
    Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
    Liu S; Huang C; Huang C; Huang Y; Yu Y; Wu G; Guo F; Jiang Y; Wan S; Zhu Z; Tian Y; Zhu J; Zhang J
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2227779. PubMed ID: 37349867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.